pioglitazone and HIV Lipodystrophy Syndrome studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

Excerpt	Relevance	Reference
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance."	9.15	Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."	7.72	Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance."	5.15	Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."	3.72	Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS."	2.46	The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010)

Research

Studies (6)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Blood Pressure

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	3 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Okada, S	1
Konishi, M	1
Ishii, H	1
Sheth, SH	1
Larson, RJ	1
Magkos, F	1
Brennan, A	1
Sweeney, L	1
Kang, ES	1
Doweiko, J	1
Karchmer, AW	1
Mantzoros, CS	1
Calmy, A	1
Hirschel, B	1
Hans, D	1
Karsegard, VL	1
Meier, CA	1
Prasithsirikul, W	1
Bunnag, P	1
Slama, L	1
Lanoy, E	1
Valantin, MA	1
Bastard, JP	1
Chermak, A	1
Boutekatjirt, A	1
William-Faltaos, D	1
Billaud, E	1
Molina, JM	1
Capeau, J	1
Costagliola, D	1
Rozenbaum, W	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]	Phase 2	112 participants (Anticipated)	Interventional	2021-08-03	Recruiting
Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients[NCT00140244]	Phase 2	7 participants (Actual)	Interventional	2001-12-31	Completed
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study[NCT00148850]	Phase 3	130 participants	Interventional	2003-02-28	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

percent change in mean blood pressure (NCT00140244)
Timeframe: At the end of each two month intervention

CD4+ Lymphocytes

Fibrinogen

Free Fatty Acid (FFA) Levels

Glycemia (as Assessed by Fasting Glucose)

Hepatic Fat Content

Insulin Levels

Insulin Resistance (as Assessed by HOMA-IR)

Interleukin-6 (IL-6) Levels

Lean Body Mass

Intervention	percentage change of mean blood pressure (Least Squares Mean)
r-MetHuLeptin	3.2
Placebo	-6.7

Intervention	cells/mcl (Mean)
r-MetHuLeptin	556.6
Placebo	637.2

Intervention	mg/dL (Mean)
r-MetHuLeptin	252.2
Placebo	294.4

Intervention	mEq/liter (Mean)
r-MetHuLeptin	0.45
Placebo	0.61

Intervention	mg/dl (Mean)
r-MetHuLeptin	91
Placebo	95.6

Intervention	percentage of liver volume (Mean)
r-MetHuLeptin	4.02
Placebo	4.01

Intervention	mcIU/ml (Mean)
r-MetHuLeptin	11.6
Placebo	20.3

Intervention	units on a scale (Mean)
r-metHuLeptin	2.52
Placebo	4.56

Intervention	pg/ml (Mean)
r-MetHuLeptin	1.65
Placebo	2.14

lean body mass (NCT00140244)
Timeframe: At the end of each two month intervention

Intervention	mg/dl (Mean)
	total cholesterol	low density lipoprotein cholesterol	triglycerides	high density lipoprotein cholesterols	Free fatty acids
Placebo	219.7	105.7	520.5	29.96	0.61
r-MetHuLeptin	228.8	113.0	409.0	35	0.45

Article	Year
Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:7 Topics: Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Mass Index; Drug Ther	2011
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS (London, England), 2003, Mar-28, Volume: 17, Issue:5 Topics: Adult; Anthropometry; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infectio	2003
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral therapy, 2008, Volume: 13, Issue:1 Topics: Adult; Double-Blind Method; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycem	2008

Article	Year
Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions. BMJ case reports, 2016, Feb-25, Volume: 2016 Topics: Antiretroviral Therapy, Highly Active; Body Fat Distribution; HIV-Associated Lipodystrophy Syndrome;	2016
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:2 Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch	2004

pioglitazone and HIV Lipodystrophy Syndrome